The phase III IMpassion130 study has met its co-primary endpoint of progression-free survival (PFS). This is the first phase III study to demonstrate a statistically significant PFS improvement in first-line metastatic or unresectable locally advanced...
Original Article: IMpassion130 study shows improved PFS in triple negative breast cancer